|
ABX464
|
AIFA website
|
2020-001673-75
|
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged ≥ 65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).
|
MiR-AGE
|
|
Acalabrutinib
|
AIFA website
|
2020-001644-25
|
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
|
ACE-ID-201
|
|
ACE inhibitors
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Acetylsalicyclic acid
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
ClinicalTrials.gov
|
NCT04808895
|
Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19
|
Asperum
|
|
Alteplase
|
ClinicalTrials.gov
|
NCT04640194
|
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
|
TRISTARDS
|
|
Anakinra
|
AIFA website
|
2020-001167-93
|
A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101)
|
Sobi.IMMUNO-101
|
|
AIFA website
|
2020-005828-11
|
Supar-guided anakinra treatment for validation of the risk and early management of severe respiratory failure by covid-19: the save-more double-blind, randomized, phase iii confirmatory trial
|
SAVE-MORE
|
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Angiotensin receptor blockers
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
AZD7442
|
AIFA website
|
2020-005315-44
|
A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults
|
TACKLE Study
|
|
Baricitinib
|
AIFA website
|
2020-001955-42
|
BARICIVID-19 STUDY: MultiCentre, randomised, Phase IIa clinical trial evaluating efficacy and tolerability of Baricitinib as add-on treatment of in-patients with COVID-19 compared to standard therapy
|
BARCIVID
|
|
AIFA website
|
2020-001854-23
|
Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19
|
AMMURAVID
|
|
AIFA website
|
2020-001517-21
|
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection
|
COV-BARRIER
|
|
AIFA website
|
2020-001185-11
|
A proof-of concept study of the use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the treatment of COVID-19-related pneumonia
|
BREATH trial
|
|
ClinicalTrials.gov
|
NCT04358614
|
Baricitinib Therapy in COVID-19
|
HPrato-4
|
|
Bevacizumab
|
Clincaltrials.gov
|
NCT04275414
|
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia
|
BEST-CP
|
|
Canakinumab
|
AIFA website
|
2020-001370-30
|
Phase 3 multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID)
|
CAN-COVID
|
|
AIFA website
|
2020-001854-23
|
Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19
|
AMMURAVID
|
|
Chloroquine
|
AIFA website
|
2020-001366-11
|
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
|
SOLIDARITY
|
|
Cholecalciferol
|
AIFA website
|
2020-002119-23
|
COVitaminD Trial: prevenzione di complicanze da COVID-19 in pazienti oncologici in trattamento attivo
|
COVitaminD
|
|
Clopidogrel
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Colchicine
|
AIFA website
|
2020-001475-33
|
Treatment with COLchicine of patients affected by COLVID-19 : a Pilot Study
|
COLVID-19
|
|
AIFA website
|
2020-001258-23
|
Colchicine To Counteract Inflammatory Response In Covid-19 Pneumonia
|
ColCOVID
|
|
AIFA website
|
2020-001806-42
|
ColcHicine in patients with COVID-19: a home CarE study
|
CHOICE-19
|
|
AIFA website
|
2020-002234-32
|
Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19)
|
CONVINCE
|
|
Convalescent plasma
|
ClinicalTrials.gov
|
NCT04385043
|
Hyperimmune Plasma in Patients With COVID-19 Severe Infection
|
COV2-CP
|
|
ClinicalTrials.gov
|
NCT04428021
|
Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure
|
PLACO-COVID
|
|
ClinicalTrials.gov
|
NCT04321421
|
Hyperimmune Plasma for Critical Patients With COVID-19
|
COV19-PLASMA
|
|
ClinicalTrials.gov
|
NCT04346589
|
Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients
| |
|
ClinicalTrials.gov
|
NCT04393727
|
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19
|
TSUNAMI
|
|
ClinicalTrials.gov
|
NCT04418531
|
Convalescent Antibodies Infusion in COVID 19 Patients
| |
|
ClinicalTrials.gov
|
NCT04374526
|
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.
|
LIFESAVER
|
|
ClinicalTrials.gov
|
NCT04569188
|
Convalescent Plasma in COVID-19 Elderly Patients
|
RESCUE
|
|
ClinicalTrials.gov
|
NCT04614012
|
Hyperimmune Plasma for Patients With COVID-19
|
IMMUNO-COVID19
|
|
ClinicalTrials.gov
|
NCT04622826
|
plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients
| |
|
ClinicalTrials.gov
|
NCT04721236
|
Early Use of Hyperimmune Plasma in COVID-19
|
COV-II-PLA
|
|
ClinicalTrials.gov
|
NCT04716556
|
TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients
| |
|
COVID-eVax
|
AIFA website
|
2020-003734-20
|
A Phase I/Ii Study To Assess The Safety And Immunogenicity Of Covid-Evax, A Candidate Plasmid Dna Vaccine For Covid-19, In Healthy Adult Volunteers
|
COVID-eVax
|
|
CPI-006
|
ClinicalTrials.gov
|
NCT04734873
|
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
| |
|
CT-P59
|
AIFA website
|
2020-003401-60
|
A Phase 2/3, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Hospitalized Patients with SARS-CoV-2 Infection
|
CT-P59 ospedalizzati
|
|
AIFA website
|
2020-003369-20
|
CT-P59A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection. - CELLTRION
|
CT-P59 non ospedalizzati
|
|
Cyclosporin-A
|
AIFA website
|
2020-003505-58
|
A proof-of-concept study of the use of Inhaled liposomal -Cyclosporin-A in the treatment of moderate COVID-19-related pneumonia: a two-step phase II clinical trial
|
INCIPIT
|
|
Dalteparin
|
AIFA website
|
2020-004285-19
|
A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
|
ACTIVE4
|
|
Darunavir/cobicistat
|
AIFA website
|
2020-001528-32
|
Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study)
|
ARCO
|
|
DAS181
|
ClinicalTrials.gov
|
NCT04354389
|
DAS181 for STOP COVID-19
| |
|
Defibrotide
|
AIFA website
|
2020-001513-20
|
Use of Defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia
|
DEF-IVID19
|
|
Edoxaban
|
AIFA website
|
2020-002234-32
|
Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19)
|
CONVINCE
|
|
Emapalumab
|
AIFA website
|
2020-001167-93
|
A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101)
|
Sobi.IMMUNO-101
|
|
Enoxaparin
|
AIFA website
|
2020-001708-41
|
Enoxaparina for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40mg o.d. versus 40mg b.i.d. A randomized Clinical Trial
|
X-COVID
|
|
AIFA website
|
2020-001972-13
|
Randomised controlled trial comparing efficacy and safety of high versus low Low- Molecular Weight Heparin dosages in hospitalised patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD)
|
COVID-19 HD
|
|
AIFA website
|
2020-001308-40
|
Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID19: a pilot phase II single-arm study, INHIXACOVID19
|
INHIXACOVID
|
|
AIFA website
|
2020-002214-40
|
EMOS-COVID - Enoxaparina
|
EMOS-COVID
|
|
AIFA website
|
2020-004285-19
|
A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
|
ACTIVE4
|
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Enoxaparin+Methylprednisolone
|
AIFA website
|
2020-001921-30
|
Steroids and unfractionated heparin in critically ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design.
|
STAUNCH
|
|
Favipiravir
|
AIFA website
|
2020-001528-32
|
Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study)
|
ARCO
|
|
AIFA website
|
2020-001115-25
|
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Inpatients with COVID-19-General Type (HS216C17
|
HS216C17
|
|
Fondaparin
|
AIFA website
|
2020-004285-19
|
A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
|
ACTIVE4
|
|
GRAd-COV2
|
AIFA website
|
2020-002835-31
|
A Phase 1, Dose-Escalation Study to assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects
|
RT-CoV-2
|
|
AIFA website
|
2020-005915-39
|
A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older. COVITAR
|
COVITAR
|
|
Heparin
|
AIFA website
|
2020-004285-19
|
A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
|
ACTIVE4
|
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Heparin+Methylprednisolone
|
AIFA website
|
2020-001921-30
|
Steroids and unfractionated heparin in critically ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design.
|
STAUNCH
|
|
Hydroxycloroquine
|
AIFA website
|
2020-001441-39
|
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)
|
COP-COV
|
|
AIFA website
|
2020-001987-28
|
PRECOV Idrossiclorochina negli operatori sanitari
|
PRECOV
|
|
AIFA website
|
2020-001501-24
|
PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19)
|
PROTECT
|
|
AIFA website
|
2020-001558-23
|
Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients (Hydro-Stop-COVID19 Trial)
|
Hydro-Stop
|
|
AIFA website
|
2020-001528-32
|
Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study)
|
ARCO
|
|
AIFA website
|
2020-001366-11
|
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
|
SOLIDARITY
|
|
Hydroxycloroquine+Azitromycin
|
AIFA website
|
2020-001802-50
|
AZI-RCT-COVID-19 - Studio sull'utilizzo di idrossiclorochina+azitromicina
|
AZI-RCT-COVID-19
|
|
hzVSF-v13
|
AIFA website
|
2020-003614-13
|
Efficacy and safety of intravenously administered hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled study
|
hzVSF_v13-0006
|
|
Interferon beta-1a
|
AIFA website
|
2020-001366-11
|
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
|
SOLIDARITY
|
|
AIFA website
|
2020-002458-25
|
Randomized, controlled, open label, phase 2 clinical trial of Interferon-β-1a (IFNβ-1a) in COVID-19 patients.
|
INTERCOP
|
|
AIFA website
|
2020-003872-42
|
Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patients
|
ANTIICIPATE
|
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Ivermectin
|
AIFA website
|
2020-002283-32
|
Randomized, Double-blind, Multi entre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the early Treatment of COVID-19
|
COVER
|
|
Lopinavir/Ritonavir
|
AIFA website
|
2020-001528-32
|
Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study)
|
ARCO
|
|
AIFA website
|
2020-001366-11
|
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
|
SOLIDARITY
|
|
MAD0004J08
|
AIFA website
|
2020-005469-15
|
COVID-19: A Phase I dose-escalation study to evaluate the safty and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody MAD0004j08 in healthy adultse
|
MAD0004J08
|
|
Mavrilimumab
|
AIFA website
|
2020-001795-15
|
A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyper-inflammation: the COMBAT-19 trial
|
COMBAT-19
|
|
Methyilprednisolone
|
AIFA website
|
2020-001854-23
|
Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19
|
AMMURAVID
|
|
AIFA website
|
2020-004323-16
|
Uno studio randomizzato multicentrico in doppio cieco per valutare l'efficacia della somministrazione di Metilprednisolone ad alte dosi in aggiunta al trattamento standard in pazienti affetti da polmonite da SARS-CoV2 - Codice: RCT-MP-COVID-19
|
RCT-MP-COVID-19
|
|
ClinicalTrials.gov
|
NCT04636671
|
Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT)
|
MEDAS
|
|
MK-4482
|
AIFA website
|
2020-003367-26
|
A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19
|
MK-4482 ospedalizzati
|
|
AIFA website
|
2020-003368-24
|
“A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Participants ≥18 Years of Age with COVID-19”
|
MK-4482 non ospedalizzati
|
|
Nafamostat Mesylate
|
ClinicalTrials.gov
|
NCT04352400
|
Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)
|
RACONA
|
|
Opaganib
|
AIFA website
|
2020-002677-95
|
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia
|
ABC-201
|
|
Oxytocin
|
ClinicalTrials.gov
|
NCT04386447
|
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
|
OsCOVID19
|
|
Pamrevlumab
|
AIFA website
|
2020-001472-14
|
An Open-Label, Randomized, Parallel-Arm Study Investigating The Efficacy And Safety Of Intravenous Administration Of Pamrevlumab Versus Standard Of Care In Patients With Covid-19
|
FibroCov
|
|
Plitidepsin
|
ClinicalTrials.gov
|
NCT04784559
|
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
|
Neptuno
|
|
Prasugrel
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
ClinicalTrials.gov
|
NCT04445623
|
Prasugrel in Severe COVID-19 Pneumonia
|
PARTISAN
|
|
Polyvalent immunoglobulins
|
AIFA website
|
2020-002058-26
|
High dose intravenous polyvalent immunoglobulin (IVIG) in patients with early inflammatory COVID-19.
|
IVIG/H/Covid-19
|
|
Raloxifene
|
AIFA website
|
2020-003936-25
|
Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID- 19 patients.
|
RLX0120
|
|
Ravulizumab
|
AIFA website
|
2020-001497-30
|
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome
|
ALXN1210-COV-305
|
|
Remdesivir
|
AIFA website
|
2020-000842-32
|
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. (GS-US-540-5774 Study)
|
GS-US-540-5774
|
|
AIFA website
|
2020-000841-15
|
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19. (GS-US-540-5773 Study)
|
GS-US-540-5773
|
|
AIFA website
|
2020-001366-11
|
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
|
SOLIDARITY
|
|
AIFA website
|
2020-001803-17
|
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 (GS-US-540-5823)
|
GS-US-540-5823
|
|
Reparixin
|
AIFA website
|
2020-001645-40
|
Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia (REPAVID-19)
|
REPAVID-19
|
|
AIFA website
|
2020-005919-51
|
Studio di fase 3, multicentrico, randomizzato, controllato con placebo, sull'efficacia e la sicurezza di Reparixin nel trattamento di pazienti ospedalizzati con polmonite grave da COVID-19
|
REPAVID-19 Phase 3
|
|
Ruxolitinib
|
AIFA website
|
2020-001662-11
|
Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia (REPAVID-19)
|
RUXCOVID
|
|
Sarilumab
|
AIFA website
|
2020-001390-76
|
ESCAPE Studio di fase 2 sull'utilizzo di sarilumab
|
ESCAPE
|
|
AIFA website
|
2020-001162-12
|
An adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 (Sarilumab COVID-19).
|
Sarilumab COVID-19
|
|
AIFA website
|
2020-001854-23
|
Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19
|
AMMURAVID*
|
|
AIFA website
|
2020-001745-40
|
Pilot study on the use of sarilumab in patients with covid-19 infection (COVID-SARI)
|
COVID-SARI
|
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Selinexor
|
AIFA website
|
2020-001411-25
|
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection (XPORT-CoV-1001)
|
XPORT-CoV-1001
|
|
Siltuximab
|
AIFA website
|
2020-001854-23
|
Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19
|
AMMURAVID
|
|
Simvastatin
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Sitagliptin
|
ClinicalTrials.gov
|
NCT04365517
|
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
|
SIDIACO
|
|
Ticagrelor
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
Tinzaparin
|
AIFA website
|
2020-004285-19
|
A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
|
ACTIVE4
|
|
Tirofiban
|
ClinicalTrials.gov
|
NCT04368377
|
Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
|
PIC-19
|
|
Tocilizumab
|
AIFA website
|
2020-001110-38
|
Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19)
|
TOCIVID-19
|
|
AIFA website
|
2020-001386-37
|
RCT-TCZ-COVID-19 somministrazione precoce del Tocilizumab
|
RCT-TCZ-COVID-19
|
|
AIFA website
|
2020-001154-22
|
A randomized, double-blind, placebocontrolled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe covid-19 pneumonia (Tocilizumab 2020-001154-22)
|
Tocilizumab 2020-001154-22
|
|
AIFA website
|
2020-001854-23
|
AMMURAVID Studio di fase 3 multiarm della SIMIT
|
AMMURAVID
|
|
AIFA website
|
2020-005291-35
|
A multicenter randomized trial to evaluate the efficacy of tocilizumab in patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia failing glucocorticoids (Anticipant Study)
|
ANTICIPANT Study
|
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
ClinicalTrials.gov
|
NCT04315480
|
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis
| |
|
Tofacitinib
|
AIFA website
|
2020-002035-30
|
TOFAcitinib plus Hydroxycloroquine vs Hydroxycloroquine in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial
|
TOFACOV-2
|
|
ClinicalTrials.gov
|
NCT04332042
|
TOFAcitinib in SARS-CoV2 Pneumonia
|
TOFACOV
|
|
Vitamin C
|
AIFA website
|
2015-002340-14
|
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
|
REMAP-CAP
|
|
ClinicalTrials.gov
|
NCT04323514
|
Use of Ascorbic Acid in Patients With COVID 19
| |
